Sunesis Pharmaceutic (SNSS) 0.81 $SNSS Sunesis
Post# of 273257
Posted On: 09/03/2016 11:25:28 PM
Sunesis Pharmaceutic (SNSS) 0.81 $SNSS
Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology's 2nd International Conference on New Concepts in B-Cell Malignancies
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that a poster detailing preliminary results from the Company's Phase 1A study in healthy volunteers evaluating oral non-covalent BTK-inhibitor SNS-062 will be presented at the European School of Haematology's 2 International Conference on New Concepts in B-Cell Malignancies being held September 9-11, 2016, at the Estoril Congress Centre in Estoril, Portugal.
SNSS: 0.81 (+0.01)
Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results from the Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 at the European School of Haematology's 2nd International Conference on New Concepts in B-Cell Malignancies
GlobeNewswire - Thu Sep 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that a poster detailing preliminary results from the Company's Phase 1A study in healthy volunteers evaluating oral non-covalent BTK-inhibitor SNS-062 will be presented at the European School of Haematology's 2 International Conference on New Concepts in B-Cell Malignancies being held September 9-11, 2016, at the Estoril Congress Centre in Estoril, Portugal.
SNSS: 0.81 (+0.01)
(0)
(0)Scroll down for more posts ▼